Search results for "Benzamide"

showing 10 items of 199 documents

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct

Current results on the use of imatinib mesylate in patients with relapsed philadelphia chromosome positive leukemia after allogeneic or syngeneic hem…

2003

Here, we describe a patient diagnosed with chronic myelogenous leukemia who relapsed after matched unrelated donor SCT. The patient was treated with imatinib mesylate and donor lymphocyte infusions, and achieved a complete molecular remission. Additionally, safety and efficacy of imatinib mesylate in a total of 134 patients from 8 centers who underwent allogeneic or syngeneic stem cell transplantation (SCT) and had a relapse of Philadelphia chromosome positive leukemia was reviewed. Data was compiled from abstracts accepted as oral or poster presentations at the ASH (American Society of Hematology) 2001 and EBMT (European Group for Blood and Marrow Transplantation) 2001 & 2002 meetings and …

AdultOncologymedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationAntineoplastic AgentsHematopoietic stem cell transplantationPolymerase Chain ReactionPiperazinesRecurrenceLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansTransplantation Homologouseducationeducation.field_of_studyHematologybusiness.industryHematopoietic Stem Cell TransplantationGeneral Medicinemedicine.diseaseSurgerySyngeneic stem cell transplantationTransplantationTransplantation IsogeneicLeukemiaPyrimidinesTreatment OutcomeImatinib mesylateBenzamidesImatinib MesylateFemalebusinessChronic myelogenous leukemiaThe Keio Journal of Medicine
researchProduct

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

2011

Background Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effect…

AgonistAdultMaleFluorine RadioisotopesPyrrolidinesmedicine.drug_classDopamineReceptors Opioid muPharmacologySeverity of Illness IndexRemifentanilRadioligand AssayDopamine receptor D1PiperidinesDopamine receptor D3DopaminemedicineLimbic SystemHumansBiological PsychiatryReceptors Dopamine D2PutamenFunctional NeuroimagingVentral striatumAlcohol dependenceMiddle AgedAnalgesics OpioidBehavior AddictiveAlcoholismmedicine.anatomical_structurenervous systemFallypridePositron-Emission TomographyBenzamidesPsychologymedicine.drugBiological psychiatry
researchProduct

Behavioral effects of different enriched environments in mice treated with the cholinergic agonist PNU-282987.

2013

Abstract Environmental enrichment is an experimental model in which rodents are housed in complex environments that favor lower levels of anxiety-like behavior. PNU-282987 (PNU) is a α7 nicotinic acetylcholine receptor agonist with beneficial effects on learning though its effects on anxiety are unclear. Our main aim was to carry out a study of its effects in NMRI ( n  = 96) mice reared in different environments: environmental enrichment (EE), Marlau™ cages (MC) and standard environment (SE). After a 4-month period, mice received acute treatment of PNU (2.5, 5 and 10 mg/kg) and were evaluated in the elevated plus-maze (EPM) and hole-board (HB). In the EPM, both EE and MC reared mice showed …

AgonistMalemedicine.medical_specialtyElevated plus mazealpha7 Nicotinic Acetylcholine Receptormedicine.drug_classAnxietyEnvironmentMotor ActivityDevelopmental psychologyBehavioral NeuroscienceBridged Bicyclo CompoundsMiceα7 nicotinic acetylcholine receptorInternal medicinemedicineAnimalsNicotinic AgonistsBeneficial effectsEnvironmental enrichmentBehavior AnimalExperimental modelGeneral MedicineNicotinic agonistEndocrinologyBenzamidesExploratory BehaviorCholinergicAnimal Science and ZoologyPsychologyInjections IntraperitonealBehavioural processes
researchProduct

Involvement of tachykinin NK2 receptors in the modulation of spontaneous motility in rat proximal colon.

2000

The role of endogenous tachykinins and the mechanisms whereby they act on NK2 receptors, modulating spontaneous motility, were investigated in rat isolated proximal colon. The mechanical activity was detected as changes in intraluminal pressure. The NK2 receptor antagonist, MEN 10627, produced a concentration-dependent reduction of the contraction amplitude. [beta-Ala8]-neurokinin A(4-10), an NK2 receptor agonist, and [Sar9, Met(O2)11]-Substance P ([Sar9, Met(O2)11]-SP), an NK1 receptor agonist, induced a concentration-dependent contractile response, characterized by an increase in basal tone with superimposed phasic contractions. MEN 10627 antagonized the response to [beta-Ala8]-neurokinin…

AgonistMalemedicine.medical_specialtyPhysiologymedicine.drug_classColonNeurokinin AInhibitory postsynaptic potentialNitric OxidePeptides CyclicTonic (physiology)chemistry.chemical_compoundPiperidinesInternal medicinemedicineAnimalsEnzyme InhibitorsRats WistarReceptorEndocrine and Autonomic SystemsChemistrymusculoskeletal neural and ocular physiologyGastroenterologyAntagonistReceptors Neurokinin-2RatsEndocrinologyNicotinic agonistNG-Nitroarginine Methyl EsterBenzamidesTetrodotoxinHexamethoniumGastrointestinal MotilityNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
researchProduct

Tachykinin NK(2) receptors facilitate acetylcholine release from guinea-pig isolated trachea.

2000

The release of newly synthesised [3H]acetylcholine was evoked by electrical field stimulation (5 Hz, 600 pulses) of epithelium-deprived guinea-pig trachea strips after sensory neuropeptides depletion with 3 microM capsaicin. The selective tachykinin NK(2) receptor agonist [betaAla(8)]neurokinin A-(4-10) increased in a concentration-dependent manner the electrically-induced release of [3H]acetylcholine. The facilitatory effect was antagonised by the selective non-peptide tachykinin NK(2) receptor antagonist, SR 48968 (apparent pK(B) 8.9). The tachykinin NK(1) and NK(3) receptor agonists substance P methyl ester and senktide (both 10 and 100 nM), respectively, did not affect the evoked releas…

AgonistMalemedicine.medical_specialtymedicine.drug_classNeurokinin AGuinea PigsSubstance PIn Vitro TechniquesCholinechemistry.chemical_compoundPiperidinesInternal medicinemedicineAnimalsReceptorPharmacologyNeuronsReceptors Neurokinin-2Receptor antagonistAcetylcholineElectric StimulationPeptide FragmentsTracheaEndocrinologychemistryCapsaicinBenzamidesNeurokinin ACapsaicinTachykinin receptorAcetylcholinemedicine.drugEuropean journal of pharmacology
researchProduct

Cooperativity of H-bonding and anion–π interaction in the binding of anions with neutral π-acceptors

2012

A rare anion-π complex between bromide and a neutral receptor is reported and related receptor systems are studied with a series of anions. The interaction is observed in the solid state and in solution, and further evidence for it is obtained by a computational study.

AnionsBromidesModels MolecularMagnetic Resonance SpectroscopyChemistryHydrogen bondInorganic chemistryChemieMolecular ConformationMetals and AlloysSolid-stateHydrogen BondingCooperativityGeneral ChemistryCatalysisSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsIonCrystallographychemistry.chemical_compoundBromideBenzamidesMaterials ChemistryCeramics and Compositesta116Chemical Communications
researchProduct

A bis(triazole)benzamide receptor for the complexation of halide anions and neutral carboxylic acid guests. Guest-controlled topicity and self-assemb…

2012

Bis(triazole)benzamide 1 has been readily synthesized by means of Cu-catalyzed 1,3-dipolar cycloaddition and its ability to bind halide anions and neutral gallic acid derivative 12GA has been theoretically and experimentally investigated. The cavity defined by the N-H amide group and the vicinal aromatic hydrogens is suitable to form H-bonding arrays with halide guests. The stability of complexes 1·Cl- and 1·Br- is very similar, as DFT calculations predict and 1H NMR titration experiments confirm. The zigzag "anti" conformation of the molecule generates two regions with complementary positive and negative potentials that favor the statistical complexation of two molecules of the neutral car…

AnionsModels Molecularchemistry.chemical_classificationStereochemistryCarboxylic acidOrganic ChemistryCarboxylic AcidsTriazoleTopicityHalideTriazolesBromineBiochemistryCycloadditionchemistry.chemical_compoundchemistryAmideBenzamidesPolymer chemistryMoleculeChlorinePhysical and Theoretical ChemistryDerivative (chemistry)Org. Biomol. Chem.
researchProduct

Synthesis and antifungal activity of new N-(1-phenyl-4-carbetoxypyrazol-5-yl)-, N-(indazol-3-yl)- and N-(indazol-5-yl)-2-iodobenzamides

2002

N-(1-Phenyl-4-carbetoxypyrazol-5-yl)-, N-(indazol-3-yl)- and N-(indazol-5-yl)-2-iodobenzamides 6, with a Benodanil-like structure, were synthesized by refluxing in acetic acid the corresponding benzotriazinones 5 with potassium iodide for 1 h in order to study the role on the antifungal activity of the N-substitution with an aromatic heterocyclic system on benzamide moiety. Among the tested iododerivatives, compounds 6d,f,g,h possess interesting activities toward some phytopathogenic fungal strains.

AntifungalAntifungal AgentsIndazolesMagnetic Resonance SpectroscopySpectrophotometry Infraredmedicine.drug_classStereochemistryColony Count MicrobialPharmaceutical Sciencechemistry.chemical_elementCarboxamideMicrobial Sensitivity TestsIodineChemical synthesisAcetic acidchemistry.chemical_compoundN-(1-phenyl-4-carbetoxypyrazol-5-yl)-2-iodobenzamides N-(indazol-3-yl)-2-iodobenzamides N-(indazol-3-yl)-2-iodobenzamides antifungal activityDrug DiscoverymedicineMoietyBenzamideChemistryFungiSettore CHIM/08 - Chimica FarmaceuticaBenzamidesPyrazolesIl Farmaco
researchProduct

Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice

2013

The role of endocannabinoids such as anandamide during atherogenesis remains largely unknown. Fatty acid amide hydrolase (FAAH) represents the key enzyme in anandamide degradation, and its inhibition is associated with subsequent higher levels of anandamide. Here, we tested whether selective inhibition of FAAH influences the progression of atherosclerosis in mice. Selective inhibition of FAAH using URB597 resulted in significantly increased plasma levels of anandamide compared to control, as assessed by mass spectrometry experiments in mice. Apolipoprotein E-deficient (ApoE(-/-)) mice were fed a high-fat, cholesterol-rich diet to induce atherosclerotic conditions. Simultaneously, mice recei…

Apolipoprotein Emedicine.medical_specialtyApolipoprotein BNeutrophilsPolyunsaturated Alkamidesmedicine.medical_treatmentIntraperitoneal injectionGene ExpressionArachidonic AcidsDiet High-FatAmidohydrolasesMicechemistry.chemical_compoundApolipoproteins EWestern blotCell MovementSuperoxidesFatty acid amide hydrolaseInternal medicinemedicineAnimalsEnzyme InhibitorsMolecular BiologyMice Knockoutbiologymedicine.diagnostic_testChemistryMacrophagesAnandamideURB597Dietary FatsEndocannabinoid systemPlaque AtheroscleroticEndocrinologyBenzamidesbiology.proteinCarbamatesCardiology and Cardiovascular MedicineEndocannabinoidsJournal of Molecular and Cellular Cardiology
researchProduct